Drug Trial Radar · NCT04411082
A Study of IMR-687 in Subjects With Beta Thalassemia
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
122
Actual
Start
Oct 16, 2020
Primary completion
Mar 11, 2022
Study completion May 4, 2022
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Imara, Inc.
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
Conditions
- β Thalassemia
Interventions
IMR-687Drug
Oral administration of once daily IMR-687
PlaceboDrug
Oral administration of once daily Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- IMR-687 Safety and TolerabilityTime frame: Baseline to Week 40
Locations
36 sites in 13 countries. Site status is shown where the registry gives one.
Herlev Hospital
Herlev, Capital Region, Denmark
Hôpital Necker-Enfants Malades
Paris, France
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, Haute-Garonn, France
Hôpital Edouard Herriot
Lyon, Rhone, France
National Center of Surgery
Tbilisi, Georgia
Medinvest - Institute of Hematology and Transfusiology
Tbilisi, Georgia
M. Zodelava Hematology Centre
Tbilisi, Borjomi, Georgia
Aghia Sofia General Children's Hospital
Athens, Attica, Greece
Laiko General Hospital of Athens
Athens, Attica, Greece
Ippokrateio General Hospital of Thessaloniki
Thessaloniki, Central Macedonia, Greece
University General Hospital of Patras
Patra, Peloponnese, Greece
Emek Medical Center
Afula, Israel
Rambam Health Care Campus
Haifa, Haifa District, Israel
Hadassah University Hospital Ein Kerem
Jerusalem, Jerusalem, Israel
The Galilee Medical Center
Nahariya, Northern District, Israel
Azienda Ospedaliera Giuseppe Brotzu
Orbassano, Turin, Italy
Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli
Orbassano, Turin, Italy
Chronic Care Center
Hazmiyeh, Lebanon
Hospital Sultanah Aminah Johor Bharu
Johor Bahru, Johor, Malaysia
Hospital Sultanah Bahiyah
Alor Star, Kedah, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Perak, Malaysia
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia
Hospital Queen Elizabeth - Kota Kinabalu
Kota Kinabalu, Sabah, Malaysia
Hospital Umum Sarawak
Kuching, Sarawak, Malaysia
Hôpital d'Enfants Rabat
Rabat, Morocco
Amsterdam Universitair Medische Centra - Academisch Medisch Centrum
Amsterdam, North Holland, Netherlands
Centre Hôpital Universitaire Farhat Hached
Sousse, Tunisia
Centre National de Greffe de la Moelle Osseuse
Tunis, Tunisia
Hospital Aziza Othmana
Tunis, Tunisia
Hacettepe Üniversitesi
Ankara, Turkey (Türkiye)
Ege Universitesi Tip Fakultesi
Izmir, Turkey (Türkiye)
Akdeniz Üniversitesi
Mersin, Mersin, Turkey (Türkiye)
Mersin Üniversitesi Tıp Fakültesi
Mersin, Mersin, Turkey (Türkiye)
Whittington Health NHS Trust
London, England, United Kingdom
University College London Hospitals NHS Foundation Trust
London, England, United Kingdom
Manchester University NHS Foundation Trust
Manchester, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.